Regenerative biotechnology
CTM Biodent Osseous
Mesenchymal stem cells for advanced oral bone regeneration and optimization of implant integration.
Cellular solution containing five million placenta-derived mesenchymal stem cells, designed to stimulate alveolar bone repair, modulate the local response, and promote dental implant integration.
Composition
Placenta-derived mesenchymal stem cells (5 million cells).
Pharmaceutical form
Cellular solution for regenerative surgical application.
Monovette with 4 ml.
Sterile 1 ml Monovette protected in a plastic container.
Therapeutic Properties
Biotechnological product that combines mesenchymal stem cells with demineralized bone matrix to stimulate bone regeneration and improve implant integration in oral bone defects.
- Alveolar bone regeneration.
- Improves dental implant integration.
- Stimulation of local osteogenesis.
- Reduction of oral inflammation.
- Increase in osteocalcin.
- Increase in osteopontin.
- Local immunological modulation.
- Promotes bone consolidation.
Mechanism of action & Clinical data
Mesenchymal stem cells (CTMs) secrete trophic factors and extracellular vesicles that reduce inflammation, inhibit apoptosis, and stimulate angiogenesis and bone formation at the application site.